- Identification of Novel Fragments Binding to the PDZ1-2 Domain of PSD-95
-
Inhibition of PSD-95 has emerged as a promising strategy for the treatment of ischemic stroke, as shown with peptide-based compounds that target the PDZ domains of PSD-95. In contrast, developing potent and drug-like small molecules against the PSD-95 PDZ domains has so far been unsuccessful. Here, we explore the druggability of the PSD-95 PDZ1-2 domain and use fragment screening to investigate if this protein is prone to binding small molecules. We screened 2500 fragments by fluorescence polarization (FP) and validated the hits by surface plasmon resonance (SPR), including an inhibition counter-test, and found four promising fragments. Three ligand efficient fragments were shown by 1H,15N HSQC NMR to bind in the small hydrophobic P0 pockets of PDZ1-2, and one of them underwent structure-activity relationship (SAR) studies. Overall, we demonstrate that fragment screening can successfully be applied to PDZ1-2 of PSD-95 and disclose novel fragments that can serve as starting points for optimization towards small-molecule PDZ domain inhibitors.
- Zang, Jie,Ye, Fei,Solbak, Sara M. ?.,H?j, Lars J.,Zhang, Mingjie,Bach, Anders
-
supporting information
p. 949 - 954
(2020/12/31)
-
- Carry over of impurities: A detailed exemplification for glycopyrrolate (NVA237)
-
The original synthesis of glycopyrrolate (NVA237) was revised and shortened into an essentially one-pot process. Without isolating the intermediates, their purification became obsolete, thereby increasing the possibility of the carry over of impurities. For that reason, the actual, potential, and theoretical impurities of the starting materials cyclopentyl mandelic acid and 1-methyl-pyrrolidin-3-ol as well as byproducts which may occur during the synthesis were thoroughly investigated; furthermore, their transformation to possible impurities in the drug substance along the new synthetic route was performed to exclude them as actual impurities in the drug substance with certainty. The question is raised how detailed such investigation-which are fairly manageable for a simple product like glycopyrrolate-need to be.
- Allmendinger, Thomas,Bixel, Dominique,Clarke, Adrian,Di Geronimo, Laura,Fredy, Jean-Wilfried,Manz, Marco,Gavioli, Elena,Wicky, Regine,Schneider, Martin,Stauffert, Fabien J.,Tibi, Markus,Valentekovic, Darko
-
supporting information
p. 1754 - 1769
(2013/01/15)
-
- SOFT ANTICHOLINERGIC ESTERS
-
Soft anticholinergic esters of the formulas: wherein R1 and R2 are both phenyl or one of R1 and R2 is phenyl and the other is cyclopentyl; R is C1-C8 alkyl, straight or branched chain; and X- is an anion with a single negative charge; and wherein each asterisk marks a chiral center; said compound having the R, S or RS stereoisomeric configuration at each chiral center unless specified otherwise, or being a mixture thereof.
- -
-
Page/Page column 9
(2008/06/13)
-
- Pharmaceutical composition for prevention and treatment of motion sickness syndrome
-
PCT No. PCT/CN94/00080 Sec. 371 Date Dec. 13, 1996 Sec. 102(e) Date Dec. 13, 1996 PCT Filed Oct. 22, 1994 PCT Pub. No. WO95/11025 PCT Pub. Date Apr. 27, 1995The present invention involves a pharmaceutical composition for preventing and treating motion sickness syndrome, the method of using it to treat motion sickness syndrome and the method for preparing phencynonate hydrochloride of alpha -configuration, the active component of the pharmaceutical composition. As compared with the known anti-motion sickness drugs, the pharmaceutical composition of the present invention showed higher efficacy and lower side effects. In addition, the pharmaceutical composition of the present invention can also be used for preventing and treating many symptoms of functional disorders of central and peripheral cholinergic system resulting from excessive central and peripheral acetyl choline.
- -
-
-
